This Article Full Text Full Text (PDF) All Versions of this Article: 116/17/1907    most recent CIRCULATIONAHA.107.708529v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eggers, K. M. Articles by Lindahl, B. Search for Related Content PubMed PubMed Citation Articles by Eggers, K. M. Articles by Lindahl, B. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease Heart Attack Related Collections Acute coronary syndromes Other diagnostic testing Chronic ischemic heart disease

(Circulation. 2007;116:1907-1914.)
© 2007 American Heart Association, Inc.

Coronary Heart Disease

Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality

Kai M. Eggers, MD; Bo Lagerqvist, MD, PhD; Per Venge, MD, PhD; Lars Wallentin, MD, PhD; Bertil Lindahl, MD, PhD

From the Departments of Medical Sciences, Cardiology (K.M.E., B. Lagerqvist, L.W., B. Lindahl) and Clinical Chemistry (P.V.), Uppsala University Hospital, Uppsala, Sweden.

Reprint requests to Kai M. Eggers, MD, Department of Medical Sciences, Cardiology, University Hospital Uppsala, S-751 85 Uppsala, Sweden. E-mail kai.eggers{at}akademiska.se

Received January 18, 2007; accepted August 10, 2007.

Background— In patients with non–ST-elevation acute coronary syndrome, any troponin elevation is associated with an increased risk for cardiovascular events. However, the prevalence and prognostic importance of persistent troponin elevation in stabilized patients after an episode of non–ST-elevation acute coronary syndrome are unknown and were therefore assessed in this study.

Methods and Results— Cardiac troponin I (cTnI) was measured in 1092 stabilized patients at 6 weeks and 3 and 6 months after enrollment in the FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC-II) trial. cTnI was analyzed with the Access AccuTnI assay with the application of different prognostic cutoffs. Outcomes were assessed through 5 years. Elevated cTnI levels >0.01 µg/L were found in 48% of the study patients at 6 weeks, in 36% at 6 months, and in 26% at all 3 measurements. cTnI elevation was associated with increased age and other cardiovascular high-risk features. The lowest tested cTnI cutoff (0.01 µg/L) was prognostically most useful and was independently predictive of mortality (hazard ratio, 2.1 [95% confidence interval, 1.3 to 3.3]; P=0.001) on multivariable analysis adjusted for cardiovascular risk factors and randomization to an invasive versus noninvasive treatment strategy, whereas it was related to myocardial infarction only on univariate analysis.

Conclusions— Persistent minor cTnI elevation can be detected frequently in patients stabilized after an episode of non–ST-elevation acute coronary syndrome with the use of a sensitive assay. Elevated cTnI levels >0.01 µg/L predict mortality during long-term follow-up. Our results emphasize the importance of further troponin testing in non–ST-elevation acute coronary syndrome patients after hospital discharge.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				T. Kempf, J.-M. Sinning, A. Quint, C. Bickel, C. Sinning, P. S. Wild, R. Schnabel, E. Lubos, H. J. Rupprecht, T. Munzel, et al. Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study Circ Cardiovasc Genet, June 1, 2009; 2(3): 286 - 292. [Abstract] [Full Text] [PDF]

				K. Pettersson, S. Eriksson, S. Wittfooth, E. Engstrom, M. Nieminen, and J. Sinisalo Autoantibodies to Cardiac Troponin Associate with Higher Initial Concentrations and Longer Release of Troponin I in Acute Coronary Syndrome Patients Clin. Chem., May 1, 2009; 55(5): 938 - 945. [Abstract] [Full Text] [PDF]

				F. S. Apple, L. A. Pearce, S. W. Smith, J. M. Kaczmarek, and M. M. Murakami Role of Monitoring Changes in Sensitive Cardiac Troponin I Assay Results for Early Diagnosis of Myocardial Infarction and Prediction of Risk of Adverse Events Clin. Chem., May 1, 2009; 55(5): 930 - 937. [Abstract] [Full Text] [PDF]

				M. S Parmar We need to address the issue of "mild troponinaemia" BMJ, February 24, 2009; 338(feb24_1): b769 - b769. [Full Text]

				H.A. Katus, E. Giannitsis, A.S. Jaffe, and K. Thygesen Higher sensitivity troponin assays: Quo vadis? Eur. Heart J., January 2, 2009; 30(2): 127 - 128. [Full Text] [PDF]

				A. H.B. Wu, S. J. Agee, Q. A. Lu, J. Todd, and A. S. Jaffe Specificity of a High-Sensitivity Cardiac Troponin I Assay Using Single-Molecule-Counting Technology Clin. Chem., January 1, 2009; 55(1): 196 - 198. [Full Text] [PDF]

				K. M. Eggers, A. S. Jaffe, L. Lind, P. Venge, and B. Lindahl Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making Clin. Chem., January 1, 2009; 55(1): 85 - 92. [Abstract] [Full Text] [PDF]

				P. Venge, S. James, L. Jansson, and B. Lindahl Clinical Performance of Two Highly Sensitive Cardiac Troponin I Assays Clin. Chem., January 1, 2009; 55(1): 109 - 116. [Abstract] [Full Text] [PDF]

				K. M. Eggers, L. Lind, H. Ahlstrom, T. Bjerner, C. Ebeling Barbier, A. Larsson, P. Venge, and B. Lindahl Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects Eur. Heart J., July 7, 2008; (2008) ehn327v1. [Abstract] [Full Text] [PDF]

				Persistent Troponin Elevation After Acute Coronary Syndrome Predicts Mortality Journal Watch Cardiology, December 5, 2007; 2007(1205): 2 - 2. [Full Text]